Read more from the company website here.
And as I mentioned previously, NMTC has 5 must-see potential catalysts right now:
-----
No. 1 NMTC Potential Catalyst - Low Float Volatility Could Grab Hold
Volatility could be the name of the game for this one.
According to Yahoo Finance, NMTC only has just above 12.34Mn shares in its float.
With so few shares available for trading, other potential catalysts (like big news) could spark a vertical move in the short-term.
-----
No. 2 NMTC Potential Catalyst - CEO Dave Rosa Interviewed On Fox Business Network (Added Company Exposure)
NeuroOne® CEO Dave Rosa Featured on Fox Business Network's 'Mornings with Maria'
EDEN PRAIRIE, Minn., Nov. 21, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces an appearance by Chief Executive Officer Dave Rosa on Fox Business Network's Mornings with Maria earlier today. The segment, which aired live at 8:45 a.m. ET, can be viewed online at on-air-mornings-with-maria.
In conversation with veteran business journalist and anchor Maria Bartiromo, Mr. Rosa discussed NeuroOne's mission in advancing a new era in neuroscience with its game-changing thin film electrode technology developed in collaboration with Mayo Clinic. NeuroOne recently announced a milestone achievement for its Evo® sEEG Electrode, receiving FDA 510(k) clearance to market the system for temporary (less than 30 day) use. Upcoming business catalysts include the market launch of the Evo® sEEG diagnostic electrode line* and progress on a new RF ablation system in development, the Company's first therapeutic electrode technology.
Mornings with Maria on Fox Business Network (6-9 AM/ET) is the number one pre-market business news program on cable. Maria Bartiromo and her guests discuss news stories -- domestic and international -- and other topics that are expected to impact the economy and markets that day.
Read the full article here.
-----
No. 3 NMTC Potential Catalyst - FDA 510(k) Clearance Is Most Exciting And Important Accomplishment To Date
NeuroOne® Receives FDA 510(k) Clearance to Market its Evo® sEEG System for Less than 30 Day Use
Company focused on manufacturing ramp for commercialization in partnership with Zimmer Biomet
EDEN PRAIRIE, Minn., Oct. 25, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market its Evo sEEG Electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain.
...
Read the full article here.
-----
No. 4 NMTC Potential Catalyst - Accelerated Milestone Payment Accomplishes Multiple Objectives (Huge News)
NeuroOne® Announces $3.5Mn Accelerated Milestone Payment from Zimmer Biomet for Evo® sEEG Electrode
Amendment provides Zimmer Biomet with 350k warrants with exercise price of $3.00 per share
EDEN PRAIRIE, Minn., Aug. 3, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that the Company entered into an amendment to its Exclusive Development and Distribution Agreement with Zimmer Biomet, Inc. ("Zimmer") that will provide the Company with a $3.5Mn accelerated payment within 10 business days which relates to certain milestone payments. In addition, Zimmer Biomet will receive a Warrant to purchase 350k shares of the Company's common st-ock, with an exercise price of $3.00 per share.
Dave Rosa, Chief Executive Officer of NeuroOne, states, "I want to thank Zimmer for all their support to date and their confidence in our business, technology and future endeavors. This agreement accomplishes multiple objectives for NeuroOne, most importantly by providing additional capital to our balance sheet in the short-term without the need for a highly dilutive financing, and further reinforcing our ongoing partnership with Zimmer."
...
Read the full article here.
-----
No. 5 NMTC Potential Catalyst - Explosive Chart History Filled With Strong Short Term Moves
NMTC has a chart filled with several breakout runs. Check it out:
